Ocrelizumab
How it works: Removing B cells →
Ocrevus
EU: Approved in the EU since 2018US: FDA approved 2017
- Molecule type
- Antibody
- Mechanism (ChEMBL)
- B-lymphocyte antigen CD20 binding agent
- Targets
- B-lymphocyte antigen CD20
- Availability
- Authorised in all EU and EEA countries. Reimbursement is decided by each country.
Approvals
Safety communications
- EMA safety letter (DHPC) · 2026-10-08
Ocrevus: Adverse event;Post-authorisation measure Source
Most-reported side effects (FDA reports)
Reports to the FDA's adverse event system (FAERS) show what people and doctors reported while taking the medicine. They do not prove the medicine caused it, and they are not rates.
61,678 reports in total, 30,995 marked serious.
- Covid-1911,573
- Fatigue6,216
- Urinary tract infection3,781
- Headache3,265
- Multiple sclerosis3,027
- Multiple sclerosis relapse2,729
- Gait disturbance2,717
- Asthenia2,707
- Nasopharyngitis2,569
- Pain2,540
Trials
Key trials
Large trials with a reported result on their main goal.
- Ocarina II
Completed · Phase 3 · Relapsing and progressive · Equivalent
- GAVOTTE
Running, not recruiting · Phase 3 · Progressive MS · Main goal not met
- MUSETTE
Running, not recruiting · Phase 3 · Relapsing MS · Main goal not met
- Ocrelizumab, phase 3
Completed · Phase 3 · Relapsing MS · Equivalent
- O'HAND
Running, not recruiting · Phase 3 · Progressive MS · Main goal met
- Ocrelizumab, phase 3
Terminated · Phase 3 · Relapsing MS · Stopped: no effect
- Ocrelizumab, phase 3
Completed · Phase 3 · Relapsing MS · Main goal met
- OPERA II
Completed · Phase 3 · Relapsing MS · Main goal met
- OPERA I
Completed · Phase 3 · Relapsing MS · Main goal met
- Oratorio
Completed · Phase 3 · Progressive MS · Main goal met
Running now
- Ocrelizumab, phase 2
Not yet recruiting · Phase 2 · Relapsing MS · ongoing
- SONATA-MS
Recruiting · Relapsing MS · ongoing
- Ocrelizumab
Recruiting · Relapsing MS · ongoing
- Mintaka
Recruiting · Phase 2 · Progressive MS · ongoing
- Glp-1
Recruiting · Relapsing and progressive · ongoing
- PORTAMENTO
Running, not recruiting · Phase 2 · Relapsing and progressive · ongoing
- Ocrelizumab, phase 4
Running, not recruiting · Phase 4 · Relapsing and progressive · ongoing
- Ocrelizumab, phase 4
Recruiting · Phase 4 · Relapsing and progressive · ongoing
- Ocrelizumab, phase 3
Running, not recruiting · Phase 3 · Relapsing and progressive · ongoing
- Ocrelizumab, phase 1
Running, not recruiting · Phase 1 · Relapsing and progressive · ongoing
Other trials (41)
Completed small trials, dose-finding studies and trials in other diseases.
- 2-mercaptoethanesulfonic acid, phase 1
Suspended · Phase 1 · Progressive MS · ongoing
- Ocrelizumab
Completed · Relapsing and progressive · no_result_found
- LEGATO
Withdrawn · Phase 4 · Progressive MS · stopped_other
- Ocrelizumab, phase 2
Withdrawn · Phase 2 · Relapsing MS · stopped_other
- MINORE
Completed · Phase 4 · Early (CIS/RIS) · results_posted_no_test
- Ocrelizumab, phase 3
Completed · Phase 3 · Relapsing and progressive · results_posted_no_test
- Ocrelizumab, phase 4
Moved to EU CTIS registry · Phase 4 · Relapsing MS
- CELLO
Terminated · Phase 4 · Early (CIS/RIS) · stopped_other
- Ocrelizumab, phase 4
Completed (inferred) · Phase 4 · Relapsing MS · no_result_found
- Ocrelizumab, phase 4
Completed · Phase 4 · Progressive MS · no_result_found
For information only, not medical advice. Talk to your neurologist before changing treatment.
Hypotheses involving this medicine
Loading hypotheses…
Loading reviews and guidelines…
Lab studies
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error